从DNA甲基化及下游MAPK信号通路探讨活血解毒中药栀子川芎胶囊抗动脉粥样硬化的机理研究

批准号:
81973679
项目类别:
面上项目
资助金额:
55.0 万元
负责人:
徐凤芹
依托单位:
学科分类:
中西医结合临床基础
结题年份:
2023
批准年份:
2019
项目状态:
已结题
项目参与者:
徐凤芹
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
微信扫码咨询
中文摘要
动脉粥样硬化(AS)为众多心血管疾病的病理基础。异常DNA甲基化涉及炎症反应、内皮损伤、平滑肌细胞增殖、泡沫细胞形成,是AS发生与发展的核心环节之一。在下游信号通路方面,MAPK信号通路的激活是AS疾病进展的重要因素。最近研究表明,在AS中DNA甲基化与下游MAPK信号通路密切相关。栀子川芎胶囊是根据瘀毒致病理论设计,前期体内外实验表明,栀子川芎胶囊抗AS效应明确。高通量测序手段发现该药能调节AS基因甲基化,KEGG数据分析发现,上述基因涉及MAPK通路。因此假设栀子川芎胶囊通过调节基因甲基化水平,进而影响下游MAPK通路核心蛋白表达从而实现抗AS效应。为验证此假设,本次研究拟采AS兔和体外细胞模型(泡沫细胞和内皮细胞模型),运用甲基化PCR及蛋白表达等技术,试图揭示栀子川芎胶囊治疗AS的新分子机制,为开发甲基化调控药物作前期探索。
英文摘要
Atherosclerosis (AS) is the pathological basis of many cardiovascular diseases. Abnormal DNA methylation involves inflammatory reaction, endothelial injury, smooth muscle cell proliferation, and foam cell formation, which plays a key part in the occurrence and development of AS. For the downstream signaling pathways, the activation of MAPK signaling pathway is an important factor in the progression of AS . Recent studies have shown that DNA methylation in AS is closely related to the downstream MAPK signaling pathway. Zhizi chuanxiong capsule was designed according to the theory of "stasis" and "toxin" . Preliminary experiments in vitro and in vivo showed that Zhizi chuanxiong capsule has a clear anti-AS effect. High-throughput sequencing showed that the drug could regulate AS gene methylation, and KEGG data analysis showed that the above genes were involved in MAPK pathway. Therefore, it is assumed that Zhizi chuanxiong capsule can achieve the anti-AS effect by regulating the level of gene methylation and thereby affecting the core protein expression of the downstream MAPK pathway. In order to verify this hypothesis, this study intends to adopt AS rabbit, foam cells and endothelial cell models, and use methylation PCR and protein expression techniques to reveal the new molecular mechanism of Zhizi chuanxiong capsule in the treatment of AS, so as to make a preliminary exploration for the development of methylation regulation drugs.
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
DOI:--
发表时间:2022
期刊:中药材
影响因子:--
作者:张艳;曹唯仪;张艳虹;张国瑗;周庆兵;贾子君;徐凤芹
通讯作者:徐凤芹
DOI:10.7661/j.cjim.20221205.220
发表时间:2023
期刊:中国中西医结合杂志
影响因子:--
作者:李丹丹;王娅;任智雄;贾子君;梅俊;张颖;周庆兵;徐凤芹
通讯作者:徐凤芹
DOI:10.1016/j.jep.2023.117188
发表时间:2023-09-21
期刊:JOURNAL OF ETHNOPHARMACOLOGY
影响因子:5.4
作者:Zhang,Yan;Li,Dandan;Xu,Fengqin
通讯作者:Xu,Fengqin
DOI:10.3389/fimmu.2023.1054014
发表时间:2023
期刊:FRONTIERS IN IMMUNOLOGY
影响因子:7.3
作者:Jia, Zijun;Mei, Jun;Zhang, Yan;Wang, Ya;Wang, Hongqin;Wang, Anlu;Xu, Fengqin;Zhou, Qingbing
通讯作者:Zhou, Qingbing
Hypermethylation Effects of Yiqihuoxue Decoction in Diabetic Atherosclerosis Using Genome-Wide DNA Methylation Analyses.
利用全基因组 DNA 甲基化分析研究益气活血汤对糖尿病动脉粥样硬化的高甲基化作用
DOI:10.2147/jir.s335374
发表时间:2022
期刊:Journal of inflammation research
影响因子:4.5
作者:Zhou QB;Chen Y;Zhang Y;Li DD;Wang HQ;Jia ZJ;Jin Y;Xu FQ;Zhang Y
通讯作者:Zhang Y
基于H2S硫疏基化修饰Keap1/Nrf2探讨川栀清方抗急性心肌缺血损伤的机制
- 批准号:--
- 项目类别:面上项目
- 资助金额:--
- 批准年份:2024
- 负责人:徐凤芹
- 依托单位:
从影响高密度脂蛋白功能及促进胆固醇转运探讨活血化瘀药(芎芍胶囊)抗动脉粥样硬化的作用机制
- 批准号:81473529
- 项目类别:面上项目
- 资助金额:72.0万元
- 批准年份:2014
- 负责人:徐凤芹
- 依托单位:
活血化瘀药(芎芍胶囊)促进动脉粥样硬化血管平滑肌细胞胆固醇跨膜转运的机制研究
- 批准号:81173385
- 项目类别:面上项目
- 资助金额:57.0万元
- 批准年份:2011
- 负责人:徐凤芹
- 依托单位:
国内基金
海外基金
